Halozyme Creates New President Role for Drug Delivery Growth
Event summary
- Halozyme appoints David Ramsay as President Drug Delivery, effective June 30, 2026.
- Ramsay brings over 30 years of experience in biotechnology and life sciences, including prior roles as Halozyme's CFO from 2003-2009 and 2013-2015.
- The newly created role focuses on driving growth of Halozyme's drug delivery technologies and managing business development and alliance management.
- Ramsay previously served as Interim Chief Financial Officer of Halozyme from March 23 to June 8, 2026.
The big picture
Halozyme's appointment of David Ramsay as President Drug Delivery underscores the company's focus on leveraging its broad technology portfolio to improve biologic delivery. With partnerships spanning Roche, Pfizer, and Eli Lilly, the move signals a push for sustainable growth through enhanced business development and alliance management. The strategic shift comes at a time when the biopharmaceutical industry is increasingly valuing innovative drug delivery solutions that reduce treatment burden and improve patient outcomes.
What we're watching
- Strategic Prioritization
- How Ramsay will establish clear strategic priorities for Halozyme's drug delivery technologies.
- Alliance Management
- Whether Ramsay can drive best-in-class business development and alliance management with industry-leading biopharmaceutical partners.
- Value Creation
- The pace at which Ramsay's leadership will accelerate value creation for Halozyme's shareholders.
Related topics